Light AI, a medical technology company, has announced the initiation of a company-funded field study in New Zealand for its QuickScan Strep A platform. The study aims to evaluate the platform's performance in detecting Group A Streptococcus (Strep A) infections, a common bacterial cause of sore throat and other illnesses.
The QuickScan platform uses artificial intelligence and optical imaging to rapidly identify Strep A from throat swabs, potentially offering a faster and more accessible diagnostic tool compared to traditional lab-based tests. The field study in New Zealand is designed to test the device in real-world clinical settings.
Details on the study's timeline, number of participants, and specific locations have not been publicly disclosed by the company as of June 16, 2026. Light AI has stated that the study is fully funded by the company and is part of its broader efforts to bring the QuickScan platform to market.
